Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

It is stated that from 30 August 2023, all travelers entering China will no longer need to undergo any COVID-19 testing.

China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

On August 13th, China's State Council issued a 24-point guideline covering six areas.

China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

On 28 July, NHSA issued the "Notice on Providing Basic Medical Security for Urban and Rural Residents in 2023 by National Healthcare Security Administration, Ministry of Finance and State Taxation Administration".

According to the forecast of GHICapital, the market size of China's dPCR industry will still maintain a high growth rate from 2020 to 2024, and the market size will grow from 2.133 billion yuan to 7.011 billion yuan, at a CAGR of 34.65%.

Recently, according to the internal announcement of Abbott Healthcare, the general manager of Abbott Electrophysiology China will be adjusted, and Liu Bei (Laura), the former senior director of Valve Therapeutics Business Unit of Edwards China, will take up this position from July 20th.

Chinese IVD instruments market grows from RMB 10.12 billion to RMB 22.32 billion by 2020 from 2016 to 2020, at a CAGR of 21.9%. Stimulated by favorable national policies and the growing demand, it is expected to reach RMB 60.99 billion in 2025 and RMB 114.62 billion in 2030, growing at a CAGR of 22.3% and 13.4% during the periods 2020-2025 and 2025-2030, respectively.